The COVAIL study was a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection in comparison to a prototype mRNA. This study enrolled 706 participants across 22 US sites including the GW VRU. The results adds to the evidence that matching COVID-19 vaccines to the currently circulating strains should provide better protection.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
Latest News
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…